vs
ASURE SOFTWARE INC（ASUR）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
ASURE SOFTWARE INC的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.0倍（$36.3M vs $35.5M），ASURE SOFTWARE INC净利率更高（-14.8% vs -304.2%，领先289.5%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 23.7%），ASURE SOFTWARE INC自由现金流更多（$5.7M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 11.2%）
Asure Software是一家软件企业，其前身为Forgent Networks，2007年9月完成品牌更名后，业务逐渐拓展至人力资本管理领域，为客户提供薪资发放、考勤管理、人才管理、人力资源管理、福利管理以及保险相关服务等解决方案。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
ASUR vs RXRX — 直观对比
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $36.3M | $35.5M |
| 净利润 | $-5.4M | $-108.1M |
| 毛利率 | 63.8% | 59.8% |
| 营业利润率 | -9.7% | -304.8% |
| 净利率 | -14.8% | -304.2% |
| 营收同比 | 23.7% | 681.7% |
| 净利润同比 | -37.5% | 39.6% |
| 每股收益（稀释后） | $-0.19 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | — | $35.5M | ||
| Q3 25 | $36.3M | $5.2M | ||
| Q2 25 | $30.1M | $19.2M | ||
| Q1 25 | $34.9M | $14.7M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | $29.3M | $26.1M | ||
| Q2 24 | $28.0M | $14.4M | ||
| Q1 24 | $31.7M | $13.8M |
| Q4 25 | — | $-108.1M | ||
| Q3 25 | $-5.4M | $-162.3M | ||
| Q2 25 | $-6.1M | $-171.9M | ||
| Q1 25 | $-2.4M | $-202.5M | ||
| Q4 24 | — | $-178.9M | ||
| Q3 24 | $-3.9M | $-95.8M | ||
| Q2 24 | $-4.4M | $-97.5M | ||
| Q1 24 | $-308.0K | $-91.4M |
| Q4 25 | — | 59.8% | ||
| Q3 25 | 63.8% | -183.8% | ||
| Q2 25 | 66.1% | -4.9% | ||
| Q1 25 | 70.6% | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | 67.2% | 53.7% | ||
| Q2 24 | 67.3% | 36.2% | ||
| Q1 24 | 71.4% | 19.1% |
| Q4 25 | — | -304.8% | ||
| Q3 25 | -9.7% | -3327.6% | ||
| Q2 25 | -15.4% | -916.8% | ||
| Q1 25 | -5.8% | -1297.9% | ||
| Q4 24 | — | -4042.4% | ||
| Q3 24 | -12.4% | -377.1% | ||
| Q2 24 | -14.9% | -697.4% | ||
| Q1 24 | -1.4% | -698.4% |
| Q4 25 | — | -304.2% | ||
| Q3 25 | -14.8% | -3135.3% | ||
| Q2 25 | -20.3% | -894.2% | ||
| Q1 25 | -6.9% | -1373.3% | ||
| Q4 24 | — | -3935.5% | ||
| Q3 24 | -13.3% | -367.5% | ||
| Q2 24 | -15.5% | -676.6% | ||
| Q1 24 | -1.0% | -662.4% |
| Q4 25 | — | $-0.17 | ||
| Q3 25 | $-0.19 | $-0.36 | ||
| Q2 25 | $-0.22 | $-0.41 | ||
| Q1 25 | $-0.09 | $-0.50 | ||
| Q4 24 | — | $-0.56 | ||
| Q3 24 | $-0.15 | $-0.34 | ||
| Q2 24 | $-0.17 | $-0.40 | ||
| Q1 24 | $-0.01 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $21.5M | $743.3M |
| 总债务越低越好 | $70.4M | $9.6M |
| 股东权益账面价值 | $193.1M | $1.1B |
| 总资产 | $447.1M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.36× | 0.01× |
8季度趋势，按日历期对齐
| Q4 25 | — | $743.3M | ||
| Q3 25 | $21.5M | $659.8M | ||
| Q2 25 | $66.0M | $525.1M | ||
| Q1 25 | $14.1M | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | $11.2M | $427.6M | ||
| Q2 24 | $20.7M | $474.3M | ||
| Q1 24 | $23.2M | $296.3M |
| Q4 25 | — | $9.6M | ||
| Q3 25 | $70.4M | $11.9M | ||
| Q2 25 | $67.4M | $14.2M | ||
| Q1 25 | $14.1M | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | $7.5M | $20.5M | ||
| Q2 24 | $6.0M | $22.9M | ||
| Q1 24 | $5.3M | — |
| Q4 25 | — | $1.1B | ||
| Q3 25 | $193.1M | $1.0B | ||
| Q2 25 | $194.3M | $919.1M | ||
| Q1 25 | $197.7M | $933.9M | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | $199.2M | $524.6M | ||
| Q2 24 | $195.5M | $584.4M | ||
| Q1 24 | $197.7M | $401.2M |
| Q4 25 | — | $1.5B | ||
| Q3 25 | $447.1M | $1.4B | ||
| Q2 25 | $505.6M | $1.3B | ||
| Q1 25 | $498.9M | $1.3B | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | $428.1M | $726.5M | ||
| Q2 24 | $420.1M | $775.9M | ||
| Q1 24 | $469.3M | $557.8M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | 0.36× | 0.01× | ||
| Q2 25 | 0.35× | 0.02× | ||
| Q1 25 | 0.07× | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | 0.04× | 0.04× | ||
| Q2 24 | 0.03× | 0.04× | ||
| Q1 24 | 0.03× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.8M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $5.7M | $-47.3M |
| 自由现金流率自由现金流/营收 | 15.6% | -133.1% |
| 资本支出强度资本支出/营收 | 0.3% | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $11.6M | $-378.3M |
8季度趋势，按日历期对齐
| Q4 25 | — | $-46.1M | ||
| Q3 25 | $5.8M | $-117.4M | ||
| Q2 25 | $3.2M | $-76.4M | ||
| Q1 25 | $2.0M | $-132.0M | ||
| Q4 24 | — | $-115.4M | ||
| Q3 24 | $1.3M | $-59.2M | ||
| Q2 24 | $2.2M | $-82.2M | ||
| Q1 24 | $-3.9M | $-102.3M |
| Q4 25 | — | $-47.3M | ||
| Q3 25 | $5.7M | $-117.6M | ||
| Q2 25 | $3.0M | $-79.6M | ||
| Q1 25 | $1.8M | $-133.8M | ||
| Q4 24 | — | $-116.7M | ||
| Q3 24 | $1.2M | $-63.8M | ||
| Q2 24 | $2.1M | $-83.4M | ||
| Q1 24 | $-4.2M | $-109.0M |
| Q4 25 | — | -133.1% | ||
| Q3 25 | 15.6% | -2272.5% | ||
| Q2 25 | 9.8% | -413.9% | ||
| Q1 25 | 5.2% | -907.4% | ||
| Q4 24 | — | -2567.7% | ||
| Q3 24 | 3.9% | -244.6% | ||
| Q2 24 | 7.5% | -578.5% | ||
| Q1 24 | -13.2% | -789.9% |
| Q4 25 | — | 3.5% | ||
| Q3 25 | 0.3% | 4.7% | ||
| Q2 25 | 0.7% | 16.4% | ||
| Q1 25 | 0.6% | 12.4% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | 0.6% | 17.5% | ||
| Q2 24 | 0.5% | 8.2% | ||
| Q1 24 | 0.8% | 48.2% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASUR
| Recurring | $31.8M | 88% |
| Lathem Time | $4.6M | 13% |
RXRX
暂无分部数据
